Full Breakdown
Eli Lilly Expands Early-Access Program for Experimental Obesity Drug Retatrutide
8/4/2026, 8:56:25 PM
Core Development: Expanded Access Now Open to Additional Patients
On August 3, Eli Lilly announced that it will permit a limited number of patients to obtain early access to retatrutide, an experimental obesity therapy, before the drug receives U.S. FDA approval. The move follows a prior instance, reported six weeks earlier, in which the company granted a single 79-year-old patient special access to the same medication.
Eligibility Criteria and Program Details
Lilly’s expanded-access program is restricted to adults 18 years or older who have refractory obesity despite having tolerated the highest approved dose of existing obesity medication. Eligible individuals must also present at least two serious or life-threatening obesity-related complications and be unable to enroll in an ongoing clinical trial of retatrutide or a comparable investigational treatment. The company said it is actively reviewing requests from health-care providers.
Clinical Background of Retatrutide
Retatrutide is designed to engage three metabolic hormones—glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon—differentiating it from Lilly’s current injectable obesity drug Zepbound, which targets GLP-1 and GIP. In an 80-week trial of adults with severe obesity and established heart disease, the highest weekly dose of retatrutide produced an average weight loss of 22.6 percent, according to Reuters.
Official Statements
A Lilly spokesperson told STAT and Reuters that providing retatrutide to a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial is “medically appropriate” and consistent with FDA guidance. The spokesperson added that the company has built an expanded-access program to facilitate such use and is reviewing provider requests.
Potential Impact on Obesity Treatment Landscape
The expanded-access initiative offers a pathway for patients with severe, treatment-resistant obesity to receive a promising therapy while formal FDA approval is pending. Lilly plans to file for retatrutide’s approval with the FDA in the first quarter of next year, and early-access experiences may inform both clinicians and regulators as the drug progresses toward market authorization.
